“BINGO" game helps researchers study perception deficits

 

Cleveland, Ohio, USA (January 3, 2012) – Bingo, a popular activity in nursing homes, senior centers and assisted-living facilities, has benefits that extend well beyond socializing. Researchers found high-contrast, large bingo cards boost thinking and playing skills for people with cognitive difficulties and visual perception problems produced by Alzheimer’s disease (AD) and Parkinson’s disease (PD).

 

“The general finding of improved performance across healthy and afflicted groups suggests the value of visual support as an easy-to-apply intervention to enhance cognitive performance,” researchers from Case Western Reserve University, Boston University and Bridgewater State University wrote.

 

The findings were reported in the article, “Bingo! Externally supported performance intervention for deficit visual search in normal aging, Parkinson’s disease, and Alzheimer’s disease,” in the journal Aging, Neuropsychology, and Cognition.

 

As people age, they begin to lose sensitivity to perceive contrasts. It is exacerbated in people with dementia, according to Grover C. Gilmore, a psychologist and dean of the Mandel School of Applied Social Sciences at Case Western Reserve University.

 

Bingo is often used in nursing homes and senior centers as a social activity, and being socially engaged helps keep the mind healthy.

 

But little is known about how visual perception problems—common in aging players—affect the way these people think and play, said Gilmore, who has done extensive testing in his Perception Lab at Case Western Reserve.

 

Researchers tested cards of different sizes, contrasts and visual complexities to find out how visual perception problems impact cognitive functions among the study’s participants: 19 younger adults, 14 individuals with probable AD, 13 AD-matched healthy adults, 17 non-demented individuals with Parkinson’s disease and 20 PD-matched healthy adults.

 

When study participants played bingo on computer-generated cards that were manipulated for brightness, size and contrast, the researchers could compare the performance among the different age and health groups.

 

With some contrast and size changes to the card, researchers reported improvement in performances. For those with mild dementia, they could perform at levels of their healthy peers. Little change was reported for people with more severe dementia.

 

Gilmore and the study’s lead investigator, Alice Cronin-Golomb from Boston University, have collaborated for two decades on projects that look at visual sensory deficits and cognition among people with dementia. For PD individuals, driving is affected by low contrasts as demonstrated in simulated fog situations.

 

They have found that boosting contrast in the living environment and also at the table enables people with dementia—who have lost the ability to distinguish between similar-contrast objects—to move safely around their homes and improve their eating.

 

For example, putting a black sofa in a white room would improve the contrast of the room and make it easier for individuals to move about. Additionally, they found that individuals with dementia actually eat more if they use a white plate and tableware on a dark tablecloth or are served food that contrasts the color of the plate.

 

Boosting contrast is among interventions known as Externally Supported Performance Interventions (ESPI). The researchers say these interventions allow people with dementia and others with visual perception deficits to live independently longer, perform daily tasks and enjoy life and having such pleasures as reading a book.

 

  • Other contributors to the study are: Boston University researchers Thomas M. Laudate, Sandy Neargarder (also from Bridgewater), Tracy E. Dunne, Karen D. Sullivan and Pallavi Joshi and Case Western Reserve University researcher Tatiana M. Riedel.

 


 

Case Western Reserve University, 03.01.2012 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…